Macrolide treatment inhibits pseudomonas aeruginosa quorum sensing in non-cystic fibrosis bronchiectasis: An analysis from the bronchiectasis and low-dose erythromycin study trial

Annals of the American Thoracic Society

Volumn 13, Issue 10, 2016, Pages 1697-1703

  Burr, Lucy D ^a,c   Rogers, Geraint B ^b   Chen, Alice C H ^a   Hamilton, Brett R ^c   Pool, Gertruida F ^c   Taylor, Steven L ^b   Venter, Deon ^c   Bowler, Simon D ^c   Biga, Sally ^c   McGuckin, Michael A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c MATER HOSPITAL   (Australia)

Author keywords

Bronchiectasis; Psuedomonas aeruginosa; Quorum sensing

Indexed keywords

ERYTHROMYCIN; MESSENGER RNA; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BRONCHIECTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FEMALE; GENE EXPRESSION; HUMAN; LOW DRUG DOSE; MALE; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; AGED; AUSTRALIA; BACTERIAL LOAD; DRUG EFFECTS; MICROBIOLOGY; MIDDLE AGED; PSEUDOMONAS INFECTIONS; RESPIRATORY SYSTEM; SPUTUM;

AGED; ANTI-BACTERIAL AGENTS; AUSTRALIA; BACTERIAL LOAD; BRONCHIECTASIS; DOUBLE-BLIND METHOD; ERYTHROMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUORUM SENSING; RESPIRATORY SYSTEM; SPUTUM;

EID: 84992574368     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201601-044OC     Document Type: Article

References (21)

1. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with noncystic fibrosis bronchiectasis: The BLESS randomized controlled trial. JAMA 2013;309:1260-1267.
2. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial. Lancet 2012;380: 660-667.
3. Hiwatashi Y, Maeda M, Fukushima H, Onda K, Tanaka S, Utsumi H, Hirano T. Azithromycin suppresses proliferation, interleukin production and mitogen-activated protein kinases in human peripheral-blood mononuclear cells stimulated with bacterial superantigen. J Pharm Pharmacol 2011;63:1320-1326.
4. Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med 2014;2:988-996.
5. Tateda K, Comte R, Pechere JC, Köhler T, Yamaguchi K, Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001;45:1930-1933.
6. Wagner T, Soong G, Sokol S, Saiman L, Prince A. Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest 2005;128:912-919.
7. Wagner VE, Bushnell D, Passador L, Brooks AI, Iglewski BH. Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: effects of growth phase and environment. J Bacteriol 2003;185:2080-2095.
8. Nalca Y, Jänsch L, Bredenbruch F, Geffers R, Buer J, Häussler S. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: A global approach. Antimicrob Agents Chemother 2006;50:1680-1688.
9. Williams P, Camara M, Hardman A, Swift S, Milton D, Hope VJ, Winzer K, Middleton B, Pritchard DI, Bycroft BW. Quorum sensing and the population-dependent control of virulence. Philos Trans R Soc Lond B Biol Sci 2000;355:667-680.
10. Hunter RC, Klepac-Ceraj V, Lorenzi MM, Grotzinger H, Martin TR, Newman DK. Phenazine content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial complexity. Am J Respir Cell Mol Biol 2012;47:738-745.
11. Kai T, Tateda K, Kimura S, Ishii Y, Ito H, Yoshida H, Kimura T, Yamaguchi K. A low concentration of azithromycin inhibits the mRNA expression of N-acyl homoserine lactone synthesis enzymes, upstream of lasI or rhlI, in Pseudomonas aeruginosa. Pulm Pharmacol Ther 2009;22:483-486.
12. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, Kumar N, Schembri MA, Song Z, Kristoffersen P, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J 2003;22:3803-3815.
13. Heurlier K, Dé nervaud V, Haas D. Impact of quorum sensing on fitness of Pseudomonas aeruginosa. Int J Med Microbiol 2006;296:93-102.
14. Paggiaro PL, Chanez P, Holz O, Ind PW, Djukanović R, Maestrelli P, Sterk PJ. Sputum induction. Eur Respir J Suppl 2002;37:3s-8s.
15. RogersGB, Cuthbertson L,Hoffman LR,Wing PA, Pope C, Hooftman DA, Lilley AK, Oliver A, Carroll MP, Bruce KD, et al. Reducing bias in bacterial community analysis of lower respiratory infections. ISME J 2013;7:697-706.
16. Köhler T, Guanella R, Carlet J, van Delden C. Quorum sensing-dependent virulence during Pseudomonas aeruginosa colonisation and pneumonia in mechanically ventilated patients. Thorax 2010;65:703-710.
17. Wilder CN, Allada G, Schuster M. Instantaneous within-patient diversity of Pseudomonas aeruginosa quorum-sensing populations from cystic fibrosis lung infections. Infect Immun 2009;77:5631-5639.
18. Diggle SP, Griffin AS, Campbell GS, West SA. Cooperation and conflict in quorum-sensing bacterial populations. Nature 2007;450:411-414.
19. Wilder CN, Diggle SP, Schuster M. Cooperation and cheating in Pseudomonas aeruginosa: The roles of the las, rhl and pqs quorumsensing systems. ISME J 2011;5:1332-1343.
20. Krasniqi S, Matzneller P, Kinzig M, Sörgel F, Hüttner S, Lackner E, Müller M, Zeitlinger M. Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy. Antimicrob Agents Chemother 2012;56:1059-1064.
21. Imamura Y, Yanagihara K, Mizuta Y, Seki M, Ohno H, Higashiyama Y, Miyazaki Y, Tsukamoto K, Hirakata Y, Tomono K, et al. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 Cells. Antimicrob Agents Chemother 2004;48:3457-3461.